Drugs / Narlumosbartmab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06302465 | May 2024 → Nov 2026 expected | bone cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Narlumosbartmab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06302465 ↗ |
| Action | Inhibit | “Narlumosbartmab, a RANKL inhibitor, can make tumor boundary clear and reduce surgical difficulty by inhibiting osteoclast.” NCT06302465 ↗ |
| Route | Other | “120mg i.h.” NCT06302465 ↗ |